Ranbaxy, others to scrap 60 drug combinations
The country's leading drug makers, including Ranbaxy Laboratories, Cipla, Cadila Pharmaceuticals, Nicholas Piramal and Wockhardt, will soon withdraw about 60 drug combinations from the market.
The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation (CDSCO), the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the ‘combination drugs' as they are "unnecessary" and may pose health hazards. The Drugs Controller General of India (DCGI) had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007. Since then, the pharma industry and the the drug authority have been locked in a legal battle.
Do you want to know more?
The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation (CDSCO), the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the ‘combination drugs' as they are "unnecessary" and may pose health hazards. The Drugs Controller General of India (DCGI) had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007. Since then, the pharma industry and the the drug authority have been locked in a legal battle.
Do you want to know more?
Comments